文献速递神经肿瘤功能神经外科

脑膜瘤患者抗癫痫药物使用与抑郁焦虑及神经认知功能的回顾性队列研究

Antiseizure medication in patients with meningioma: a retrospective cohort study on the long-term impact on depression, anxiety and neurocognitive functioning.
PubMed 文献 · J Neurooncol · 2025-06-06

本研究为多中心回顾性队列研究,纳入187例脑膜瘤患者,通过神经认知测试、HADS问卷和病历资料收集数据,采用多因素logistic回归分析抗癫痫药物(ASM)使用与抑郁、焦虑及神经认知障碍的关联。结果显示,使用ASM组(n=41)与未使用组(n=146)在抑郁、焦虑和认知障碍患病率上无显著差异(aOR分别为0.81、0.63、1.42)。

要点

  • 脑膜瘤患者使用ASM与抑郁、焦虑及认知障碍无显著关联。
  • 左乙拉西坦因样本量限制未能单独进行统计分析。
  • 结果提示ASM使用未增加神经精神副作用风险。

核心结论

  • 脑膜瘤患者中ASM使用与情绪及神经认知功能障碍无显著关联。

研究设计与样本

  • 多中心回顾性队列研究,纳入187例脑膜瘤患者,收集神经认知测试、HADS问卷及病历数据,采用多因素logistic回归分析。

主要发现

  • 使用ASM组(n=41)与未使用组(n=146)的抑郁患病率无显著差异(aOR=0.81;95%CI 0.26-2.54)。
  • 焦虑患病率两组无显著差异(aOR=0.63;95%CI 0.22-1.82)。
  • 认知障碍患病率两组无显著差异(aOR=1.42;95%CI 0.51-3.98)。

临床怎么用

  • 对于脑膜瘤患者,不应因担忧抑郁、焦虑或认知副作用而回避必要的ASM治疗。

局限性

  • 左乙拉西坦使用与抑郁、焦虑及神经认知障碍的关联因样本量限制未能进行统计分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with meningiomas often suffer from brain tumor-related epilepsy for which they are prescribed antiseizure medication (ASM). ASMs have been associated with neuropsychiatric side effects such as depression, anxiety, and cognitive impairments. However, the association between ASM use and mood and cognition in meningioma patients remains unclear. In this study, we aimed to investigate the association of ASM use, and specifically the use of levetiracetam, with depression, anxiety, and neurocognitive functioning. METHODS: In this multicentre retrospective study, data from 187 meningioma patients were collected from neurocognitive tests, the HADS questionnaire, and medical records. Multivariable logistic regression analyses were used to evaluate the association between ASM use, and depression, anxiety and neurocognitive impairment. Potential confounders were included based on the existing literature. Due to sample size limitations, the association of levetiracetam use with depression, anxiety and neurocognitive impairment could not be statistically analyzed. RESULTS: The prevalence of depression, anxiety and cognitive impairment did not differ significantly for patients using ASM (n = 41) as compared to patients not using ASM (n = 146) (aOR = 0.81; 95% CI 0.26-2.54; aOR = 0.63; 95% CI 0.22-1.82; aOR = 1.42; 95% CI 0.51-3.98). CONCLUSION: Our findings show no significant association between ASM use and mood and neurocognitive dysfunction in meningioma patients.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Laribi L, Scheepens JCC, Zamanipoor Najafabadi AH, et al. Antiseizure medication in patients with meningioma: a retrospective cohort study on the long-term impact on depression, anxiety and neurocognitive functioning. J Neurooncol. 2025. PMID: 40478500. doi:10.1007/s11060-025-05025-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。